Program
tirabrutinib
Also written as “Tirabrutinib” and “ONO-4059”.
Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Pemphigus · Chronic Urticaria · Lymphoma, Non-Hodgkin · Sjogren's Syndrome, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Gilead Sciences | 80 open or running | phase 2since Nov 16, 2016 | Jul 6, 2012 | none ahead |
| Ono Pharmaceutical | 54 open or running | phase 3since Nov 7, 2024 | Jun 16, 2021 | Sep 30, 2027phase 3 · NCT06696716 |
Also a collaborator on its studies: Lakefront Biotherapeutics NV.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 6, 2012First study: phase 1 study in Lymphoma, Non-HodgkinNew to Gilead SciencesGilead Sciences · NCT01659255 · 90 enrolled · France, United Kingdom
- May 27, 20152 phase 1 studiesGilead Sciences · NCT02457598, NCT02457559
- Dec 3, 2015Phase 1 study in Arthritis, RheumatoidGilead Sciences · NCT02626026 · 42 enrolled · United States
- Nov 16, 2016Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellGilead Sciences · NCT02968563 · 35 enrolled · Germany
- Dec 2, 2016Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellGilead Sciences · NCT02983617 · 36 enrolled · Germany
- Mar 31, 2017Phase 2 study in Sjogren's SyndromeGilead Sciences · NCT03100942 · 152 enrolled · United States, Poland, Spain and more
- Mar 30, 2021Phase 2 study in Chronic UrticariaGilead Sciences · NCT04827589
- Jun 16, 2021Ono Pharmaceutical’s first study: phase 2 study in Refractory Primary Central Nervous System LymphomaNew to Ono PharmaceuticalOno Pharmaceutical · NCT04947319 · 119 enrolled · United States
- Aug 2, 2024Phase 1 study in Primary Central Nervous System LymphomaOno Pharmaceutical · NCT06541665 · 20 enrolled · Japan
- Nov 7, 2024Phase 3 study in PemphigusOno Pharmaceutical · NCT06696716 · 34 enrolled · Japan
- Jul 29, 2025Phase 3 study in RecurrenceOno Pharmaceutical · NCT07104032 · 132 planned · United States, Australia, Brazil and more
- Aug 31, 2025Phase 1 study in Primary Central Nervous System Lymphoma (PCNSL)Ono Pharmaceutical · NCT07198087 · 40 enrolled · United States
Ahead
- Sep 30, 2027Primary completion: phase 3 study in PemphigusOno Pharmaceutical · NCT06696716
- Dec 2027Primary completion: phase 3 study in RecurrenceOno Pharmaceutical · NCT07104032
- Apr 28, 2028Primary completion: phase 1 study in Primary Central Nervous System LymphomaOno Pharmaceutical · NCT06541665
TargetBeta
“An orally available formulation containing an inhibitor of Bruton agammaglobulinemia tyrosine kinase (BTK), ”NCIt, by rule
“Tyrosine-protein kinase BTK inhibitor”ChEMBL 37, by rule
Other programs on BTK
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ibrutinibrule | Johnson & Johnson | phase 4 | 78 |
| acalabrutinibrule | AstraZeneca | phase 4 | 55 |
| zanubrutinibrule | BeOne Medicines | phase 4 | 35 |
| pirtobrutinibrule | Eli Lilly | phase 4 | 30 |
| ritlecitinibrule | Pfizer | phase 3 | 42 |
| orelabrutinibrule | InnoCare Pharma | phase 3 | 27 |
| rilzabrutinibrule | Sanofi | phase 3 | 23 |
| evobrutinibrule | Merck KGaA, Darmstadt, Germany | phase 3 | 20 |
| fenebrutinib | Hoffmann-La Roche | phase 3 | 18 |
| nemtabrutinib | Merck | phase 3 | 16 |
| rocbrutinibrule | Lupeng Pharmaceutical | phase 3 | 15 |
| birelentinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07198087Primary Central Nervous System Lymphoma (PCNSL) · United States | 1 | Completed | Ono Pharmaceutical | Apr 9, 2026 | 40 |
| NCT07104032Recurrence · United States, Australia, Brazil and more | 3 | Recruiting | Ono Pharmaceutical | Dec 2027 | 132 |
| NCT06696716Pemphigus · Japan | 3 | Active, not recruiting | Ono Pharmaceutical | Sep 30, 2027 | 34 |
| NCT06541665Primary Central Nervous System Lymphoma · Japan | 1 | Active, not recruiting | Ono Pharmaceutical | Apr 28, 2028 | 20 |
| NCT04947319Refractory Primary Central Nervous System Lymphoma · United States | 2 | Active, not recruiting | Ono Pharmaceutical | Jan 27, 2026 | 119 |
| NCT04827589Chronic Urticaria | 2 | Withdrawn | Gilead Sciences | Apr 2022 | 0 |
| NCT03100942Sjogren's Syndrome · United States, Poland, Spain and more | 2 | Completed | Gilead Sciences | Jan 10, 2019 | 152 |
| NCT02983617Leukemia, Lymphocytic, Chronic, B-Cell · Germany | 2 | Completed | Gilead Sciences | Feb 20, 2019 | 36 |
| NCT02968563Leukemia, Lymphocytic, Chronic, B-Cell · Germany | 2 | Completed | Gilead Sciences | Jun 17, 2019 | 35 |
| NCT02626026Arthritis, Rheumatoid · United States | 1 | Completed | Gilead Sciences | Sep 1, 2016 | 42 |
| NCT02457598B-cell Malignancies · United States, France, United Kingdom | 1 | Terminated | Gilead Sciences | Sep 25, 2024 | 203 |
| NCT02457559Recurrence · France, United Kingdom | 1 | Completed | Gilead Sciences | Dec 30, 2020 | 29 |
| NCT01659255Lymphoma, Non-Hodgkin · France, United Kingdom | 1 | Completed | Gilead Sciences | Feb 23, 2015 | 90 |
How it is read
Names in the registry
- “Tirabrutinib”, 13 entries
- “ONO-4059”, 2 entries
Conditions, from the studies’ own filings
- Leukemia, Lymphocytic, Chronic, B-Cell, 2 studies
- Pemphigus, 1 study
- Chronic Urticaria, 1 study
- Lymphoma, Non-Hodgkin, 1 study
- Sjogren's Syndrome, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.